Yu U Jiang

US Patent:

6727264, Apr 27, 2004

Filed:

Jul 3, 2002

Appl. No.:

10/188434

Inventors:

Mohammad R. Marzabadi - Ridgewood NJ
John Wetzel - Fairlawn NJ
John E. DeLeon - North Bergen NJ
Yu Jiang - Jersey City NJ
Chien-An Chen - Fresh Meadows NY
Kai Lu - Elmwood Park NJ

Assignee:

Synaptic Pharmaceutical Corporation - Paramus NJ

International Classification:

A61K 31445

US Classification:

514323, 514331, 546200, 546234

Abstract:

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therepeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

US Patent:

7067534, Jun 27, 2006

Filed:

Nov 21, 2003

Appl. No.:

10/719358

Inventors:

Mohammad R. Marzabadi - Ridgewood NJ, US
John Wetzel - Fairlawn NJ, US
John E. DeLeon - North Bergen NJ, US
Yu Jiang - Jersey City NJ, US
Chien-An Chen - Flushing NY, US
Kai Lu - Lake Hiawatha NJ, US

Assignee:

H. Lundbeck A/S - Valby-Copenhagen

International Classification:

A61K 31/445
C07D 401/06

US Classification:

514323, 514331, 546201, 546234

Abstract:

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

US Patent:

7105544, Sep 12, 2006

Filed:

Jan 14, 2003

Appl. No.:

10/345063

Inventors:

Mohammad R. Marzabadi - Ridgewood NJ, US
John M. Wetzel - Fair Lawn NJ, US
Chien-An Chen - Flushing NY, US
Yu Jiang - Jersey City NJ, US
Kai Lu - Lake Hiawatha NJ, US

Assignee:

Synaptic Pharmaceutical Corporation - Paramus NJ

International Classification:

A61K 31/445
C07D 211/26

US Classification:

514331, 514318, 546200, 546233, 546234

Abstract:

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

US Patent:

7199135, Apr 3, 2007

Filed:

Jan 6, 2004

Appl. No.:

10/753057

Inventors:

Mohammad R. Marzabadi - Ridgewood NJ, US
John M. Wetzel - Athens OH, US
Chien-An Chen - Fresh Meadows NY, US
Yu Jiang - Jersey City NJ, US
Kai Lu - Elmwood Park NJ, US

Assignee:

H. Lundbeck A/S - Copenhagen-Valby

International Classification:

A61K 31/445
C07D 401/04

US Classification:

514318, 546193, 546194

Abstract:

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

US Patent:

7329656, Feb 12, 2008

Filed:

Sep 21, 2005

Appl. No.:

11/231601

Inventors:

Mohammad R. Marzabadi - Ridgewood NJ, US
Yu Jiang - Jersey City NJ, US
Chien-An Chen - Flushing NY, US
Kai Lu - Lake Hiawatha NJ, US
Kim Andersen - Ridgewood NJ, US

Assignee:

H. Lundbeck A/S - Valby

International Classification:

A61K 31/4545
A61K 31/444
A61K 31/5377
C07D 211/04
C07D 401/04
C07D 413/14

US Classification:

5142315, 514326, 514318, 546193, 546194, 546207, 544124, 544129

Abstract:

This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.

US Patent:

7335665, Feb 26, 2008

Filed:

Jul 3, 2003

Appl. No.:

10/518939

Inventors:

Mohammad R. Marzabadi - Ridgewood NJ, US
Yu Jiang - Jersey City NJ, US
Kai Lu - Lake Hiawatha NJ, US
Chien-An Chen - Flushing NY, US
John E. De Leon - North Bergen NJ, US
John Wetzel - Fairlawn NJ, US
Kim Andersen - Ridgewood NJ, US

Assignee:

H - Lundbeck A/S - Valby

International Classification:

A61K 31/438
C07D 221/20
C07D 491/10

US Classification:

514278, 546 17

Abstract:

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.

US Patent:

7446204, Nov 4, 2008

Filed:

Sep 20, 2005

Appl. No.:

11/230849

Inventors:

Mohammad R. Marzabadi - Ridgewood NJ, US
Chien-An Chen - Flushing NY, US
Yu Jiang - Jersey City NJ, US
Kai Lu - Lake Hiawatha NJ, US
Kim Andersen - Ridgewood NJ, US

Assignee:

H. Lundbeck A/S - Valby - Copenhagen

International Classification:

C07D 211/14
A61K 31/451

US Classification:

546247, 514315

Abstract:

This invention is directed to Amino substituted Aryloxybenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.

US Patent:

7473698, Jan 6, 2009

Filed:

Jul 3, 2003

Appl. No.:

10/518675

Inventors:

Mohammad R. Marzabadi - Ridgewood NJ, US
Yu Jiang - Jersey City NJ, US
Kai Lu - Lake Hiawatha NJ, US
Chien-An Chen - Flushing NY, US
John E. De Leon - North Bergen NJ, US
John Wetzel - Fairlawn NJ, US

Assignee:

H. Lunbeck A/S - Valby - Copenhagen

International Classification:

A61K 31/4465

US Classification:

514331, 546234

Abstract:

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compounds of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.